Potential pathologic markers for prostate chemoprevention studies

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 227-235

  Sakr, Wael A ^a   Lucia, M Scott ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CETUXIMAB; COMPLEMENTARY DNA; DNA FRAGMENT; SELENIUM; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; CANCER GRADING; CANCER PREVENTION; CELL CYCLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPUTER ANALYSIS; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; MICROVASCULATURE; MOLECULAR BIOLOGY; NEEDLE BIOPSY; NUMERICAL CHROMOSOME ABERRATION; PLOIDY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REGULATORY MECHANISM; REVIEW; STRUCTURAL CHROMOSOME ABERRATION; VALIDATION PROCESS;

ADENOCARCINOMA; AGED; CHEMOPREVENTION; DIETARY SUPPLEMENTS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SELENIUM; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 2342504585     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.03.001     Document Type: Review

References (59)

1. Sakr W.A., Haas G.P., Cassin B.J., Pontes J.E., Crissman J.D. Frequency of prostatic intraepithelial neoplasia and invasive carcinoma in young males. J Urol. 150:(2 pt 1):1993;379-385
2. Kelloff G.J., Sigman C.C., Johnson K.M., Boone C.W., Greenwald P., Crowell J.A., et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 9:(2):2000;127-137
3. Berger A.P., Spranger R., Kofler K., Steiner H., Bartsch G., Horninger W. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate. 57:(2):2003;93-98
4. San Francisco I.F., DeWolf W.C., Rosen S., Upton M., Olumi A.F. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol. 169:(1):2003;136-140
5. Klein E.A., Lippman S.M., Thompson I.M., Goodman P.J., Albanes D., Taylor P.R., et al. The selenium and vitamin E cancer prevention trial. World J Urol. 21:(1):2003;21-27
6. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:(3):2003;215-224
7. McNeal J.E., Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 17:(1):1986;64-71
8. Qian J., Wollan P., Bostwick D.G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol. 28:(2):1997;143-148
9. Sakr W.A., Billis A., Ekman P., Wilt T., Bostwick D.G. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephrol Suppl. 205:2000;11-18
10. Epstein J.I., Potter S.R. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol. 166:(2):2001;402-410
11. O'Dowd D.J., Miller M.C., Orozco R., Veltri R.W. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology. 55:(4):2000;553-558
12. Kronz J.D., Allan C.H., Shaikh A.A., Epstein J.I. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol. 25:(8):2001;1079-1085
13. Hoedemaeker R.F., Kranse R., Rietbergen J.B., Kruger A.E., Schroder F.H., van der Kwast T.H. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer. 85:(1):1999;145-152
14. Davidson D., Bostwick D.G., Qian J., Wollan P.C., Oesterling J.E., Rudders R.A., et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol. 154:(4):1995;1295-1299
15. Shepherd D., Keetch D.W., Humphrey P.A., Smith D.S., Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol. 156:(2 Pt 1):1996;460-462
16. Bostwick D.G., Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology. 58:(2 Suppl 1):2001;91-93
17. Sakr W.A., Grignon D.J., Haas G.P. Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin Urol Oncol. 16:(4):1998;214-220
18. Sinha R., El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets. 4:(1):2004;13-28
19. Saraste A. Morphologic criteria and detection of apoptosis. Herz. 24:(3):1999;189-195
20. Stadelmann C., Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res. 301:(1):2000;19-31
21. Allen R.T., Hunter W.J. III, Agrawal D.K. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 37:(4):1997;215-228
22. Gown A.M., Willingham M.C. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem. 50:(4):2002;449-454
23. Duan W.R., Garner D.S., Williams S.D., Funckes-Shippy C.L., Spath I.S., Blomme E.A. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 199:(2):2003;221-228
24. Steel G.G. The case against apoptosis. Acta Oncol. 40:(8):2001;968-975
25. Venkateswaran V., Fleshner N.E., Klotz L.H. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol. 168:(4 Pt 1):2002;1578-1582
26. Waters D.J., Shen S., Cooley D.M., Bostwick D.G., Qian J., Combs G.F. Jr., et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst. 95:(3):2003;237-241
27. Pruthi R.S., Derksen E., Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. Urol. 169:(6):2003;2352-2359
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:(1):1995;27-31
29. Pepper M.S. Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol. 17:(4):1997;605-619
30. Hrouda D., Nicol D.L., Gardiner R.A. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res. 30:(6):2003;347-355
31. Karashima T., Sweeney P., Slaton J.W., Kim S.J., Kedar D., Izawa J.I., et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 8:(5):2002;1253-1264
32. Brawer M.K., Deering R.E., Brown M., Preston S.D., Bigler S.A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 73:(3):1994;678-687
33. Brawer M.K. Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer. 78:(2):1996;345-349
34. Borre M., Offersen B.V., Nerstrom B., Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer. 78:(7):1998;940-944
35. Moul J.W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol. 35:(5-6):1999;399-407
36. Lissbrant I.F., Lissbrant E., Damber J.E., Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol. 35:(6):2001;437-452
37. Barth P.J., Weingartner K., Kohler H.H., Bittinger A. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation. Hum Pathol. 27:(12):1996;1306-1310
38. Rubin M.A., Buyyounouski M., Bagiella E., Sharir S., Neugut A., Benson M., et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 53:(3):1999;542-547
39. Gettman M.T., Bergstralh E.J., Blute M., Zincke H., Bostwick D.G. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology. 51:(1):1998;79-85
40. Bartels P.H., Montironi R., Hamilton P.W., Thompson D., Vaught L., Bartels H.G. Nuclear chromatin texture in prostatic lesions II. PIN and malignancy associated changes. Anal Quant Cytol Histol. 20:(5):1998;397-406
41. Mairinger T., Mikuz G., Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate. 41:(1):1999;12-19
42. Montironi R., Filho A.L., Santinelli A., Mazzucchelli R., Pomante R., Colanzi P., et al. Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. Morphometric analysis in whole-mount sections. Virchows Arch. 437:(6):2000;625-634
43. Mommers E.C., Poulin N., Meijer C.J., Baak J.P., van Diest P.J. Malignancy-associated changes in breast tissue detected by image cytometry. Anal Cell Pathol. 20:(4):2000;187-195
44. Ikeda N., MacAulay C., Lam S., LeRiche J., Payne P., Garner D., et al. Malignancy associated changes in bronchial epithelial cells and clinical application as a biomarker. Lung Cancer. 19:(3):1998;161-166
45. Miller G.J., Cygan J.M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 152:(5 Pt 2):1994;1709-1713
46. Miet S.M., Neyra M., Jaques R., et al. RER(1) phenotype in prostate intraepithelial neoplasia associated with human prostate carcinoma development. Int J Cancer. 82:(5):1999;635-639
47. Qian J., Jenkins R.B., Bostwick D.G. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluoresence in situ hybridization. Eur Urol. 35:1999;479-483
48. Zitzelsberger H., Kulka U., Lehmann L., et al. Genetic heterogeneity in a prostatic carcinoma and associated intraepithelial neoplasia as demonstrated by combined use of lasermicrodissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch. 433:1998;297-304
49. Jenkins R.B., Qian J., Lieber M.M., et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57:1997;524-531
50. Ha P.K., Califano J.A. The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med. 14:(5):2003;363-369
51. Qian J., Bostwick D.G., Takahashi S., Borell T.J., Herath J.F., Lieber M.M., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 55:(22):1995;5408-5414
52. Chaib H., MacDonald J.W., Vessella R.L., Washburn J.G., Quinn J.E., Odman A., et al. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer. 37:(3):2003;306-313
53. Sommerfeld H.J., Meeker A.K., Piatyszek M.A., Bova G.S., Shay J.W., Coffey D.S. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56:(1):1996;218-222
54. Liu B.C., LaRose I., Weinstein L.J., Ahn M., Weinstein M.H., Richie J.P. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer. 92:(7):2001;1943-1948
55. Bettendorf O., Heine B., Kneif S., Eltze E., Semjonow A., Herbst H., et al. Expression-patterns of the RNA component (hTR) and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer. Prostate. 55:(2):2003;99-104
56. Miller G.J., Miller H.L., van Bokhoven A., Lambert J.R., Werahera P.N., Schirripa O., et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res. 63:(18):2003;5879-5888
57. Cillo C., Cantile M., Faiella A., Boncinelli E. Homeobox genes in normal and malignant cells. J Cell Physiol. 188:(2):2001;161-169
58. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2:(10):2002;777-785
59. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R., Doody L.A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem Suppl. 19:1994;1-9